Influence of excipients in comilling on mitigating milling-induced amorphization or structural disorder of crystalline pharmaceutical actives

Journal of Pharmaceutical Sciences

Volumn 99, Issue 5, 2010, Pages 2462-2474

  Balani, Prashant N ^a   Ng, Wai Kiong ^b   Tan, Reginald B H ^a,b   Chan, Sui Yung ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUTE OF CHEMICAL AND ENGINEERING SCIENCES   (Singapore)

Author keywords

Crystallinity; Excipients; Milling; Stability; X ray powder diffractometry

Indexed keywords

ADIPIC ACID; ALPHA LACTOSE; CRYSTALLIN; EXCIPIENT; MAGNESIUM STEARATE; POVIDONE; SALBUTAMOL SULFATE;

ARTICLE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; HUMIDITY; X RAY POWDER DIFFRACTION;

EID: 77951270694     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21998     Document Type: Article

References (58)

1. Chikhalia V, Forbes RT, Storey RA, Ticehurst M. 2006. The effect of crystal morphology and mill type on milling induced crystal disorder. Eur J Pharm Sci 27:19-26.
2. Begat P, Young PM, Edge S, Kaerger JS, Price R. 2003. The effect of mechanical processing on surface stability of pharmaceutical powders: Visualization by atomic force microscopy. J Pharm Sci 92:611-619.
3. Mackin L, Sartnurak S, Thomas I, Moore S. 2002. The impact of low levels of amorphous material (<5%) on the blending characteristics of a direct compression formulation. Int J Pharm 231:213-226.
4. Feng T, Rodolfo P, Carvajal MT. 2008. Process induced disorder in crystalline materials: Differentiating defective crystals from the amorphous form of griseofulvin. J Pharm Sci 97:3207-3221.
5. Shaktshneider TP. 1997. Phase transformations and stabilization of metastable states of molecular crystals under mechanical activation. Solid State Ionics 101-103:851-856.
6. Dudognon E, Willart JF, Caron V, Capet F, Larsson T, Descamps M. 2006. Formation of budesonide/ alpha-lactose glass solutions by ball-milling. Solid State Commun 138:68-71.
7. Font J, Muntasell J, Cesari E. 1997. Amorphization of organic compounds by ball milling. Mater Res Bull 32:1691-1696.
8. Vippagunta SR, Brittain HG, Grant DJW. 2001. Crystalline solids. Adv Drug Del Rev 48:23-26.
9. Guinot S, Leveiller F. 1999. The use of MTDSC to assess the amorphous content of a micronized drug substance. Int J Pharm 192:63-75.
10. Shakhtshneider TP, Danède F, Capet F, Willart JF, Descamps M, Paccou L, Surov EV, Boldyreva EV, Boldyrev VV. 2007. Grinding of drugs with pharmaceutical excipients at cryogenic temperatures. Part II. Cryogenic grinding of indomethacin-polyvinylpyrrolidone mixtures. J Ther Anal Chem 89: 709-715. (Pubitemid 47351762)
11. Bahl D, Bogner RH. 2006. Amorphization of indomethacin by co-grinding with neusilin US2: Amorphization kinetics, physical stability and mechanism. Pharm Res 23:2317-2325.
12. Watanabe T, Wakiyama N, Usui F, Ikeda M, Isobe T, Senna M. 2001. Stability of amorphous indomethacin compounded with silica. Int J Pharm 226:81-91.
13. 13 solid state NMR. Int J Pharm 248:123-129.
14. Gupta MK, Vanwert A, Bogner RH. 2003. Formation of physically stable amorphous drugs by milling with Neusilin. J Pharm Sci 92:502-517.
15. Oguchi T, Kazam K, Yonemochi E, Churimaworapan S, Choi WS, Limmatvapirat S, Yamamoto K. 2000. Specific complexation of ursodeoxycholic acid with guest compounds induced by co-grinding. Phys Chem Chem Phys 2:2815-2820.
16. Ward GH, Shultz RK. 1995. Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability. Pharm Res 12:773-779.
17. Pfeiffer KB, Häusler H, Graß P, Langguth P. 2003. Condition following powder micronization: Influence on particle growth of salbutamol sulfate. Drug Dev Ind Pharm 29:1077-1084.
18. Pfeiffer KB, Langguth P, Häusler H, Graß P. 2003. Influence of mechanical activation on the physical stability of salbutamol sulphate. Eur J Pharm Biopharm 56:393-400.
19. Tee SK, Marriott C, Zeng XM, Martin GP. 2000. The use of different sugars as fine and coarse carriers for aerosolized salbutamol sulphate. Int J Pharm 208:111-123.
20. Islam N, Stewart P, Larson I, Hartley P. 2004. Lactose surface modification decantation: Are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixture? Pharm Res 21:492-499.
21. Louey MD, Stewart PJ. 2002. Particle interaction involved in aerosol dispersion of ternary interactive mixtures. Pharm Res 19:1524-1531.
22. Chow KY, Go J, Mehdizadeh M, Grant DJW. 1984. Modification of adipic acid crystals: Influence of growth in the presence of fatty acid additives on crystal properties. Int J Pharm 20:3-24.
23. Leinonen UI, Jalonen HU, Vihervaara PA, Laine ESU. 1992. Physical and lubrication properties of magnesium stearate. J Pharm Sci 81:1194-1198.
24. Akbuga J, Gursoy A, Kendi E. 1988. The preparation and stability of fast release furosemide-PVP solid dispersion. Drug Dev Ind Pharm 14:1439-1464.
25. Kondo N, Iwao T, Hirai KT, Fukuda M, Yamamouchi K. 1994. Improved oral absorption of enteric coprecipitate of a poorly soluble drug. J Pharm Sci 83:566-570.
26. Yagi N, Terashima T, Kenmotsu T, Sekikawa H, Takada M. 1996. Dissolution behavior of probucol from solid dispersion systems of probucol- polyvinylpyrrolidone. Chem Pham Bull 44:241-244.
27. Margarit MV, Martin MT, Contreras MD. 2001. Solubility of solid dispersions of pizotifen maleate and povidone. Drug Dev Ind Pharm 27:517-522.
28. Watanabe T, Hasegawa S, Wakiyama N, Kusai A, Senna M. 2003. Comparison between polyvinylpyrrolidone and silica nanoparticles as carriers for indomethacin in a solid state dispersion. Int J Pharm 250:283-286.
29. Mackin L, Zanon R, Park JM, Foster K, Opalenik H, Demonte M. 2002. Quantification of low levels (<10%) of amorphous content in micronised active batches using dynamic vapour sorption and isothermal microcalorimetry. Int J Pharm 231:227-236.
30. Lehto VP, Tenho M, Vähä-heikkilä K, Harjunen P, Päällysaho M, Välisaari J, Niemelä P, Järvinen K. 2006. The comparison of seven different methods to quantify the amorphous content of spray dried lactose. Powder Tech 167:85-93.
31. Matthias G, Jakobs M, Mykhaylova V, Urbanetz NA. 2007. Quantifying the degree of disorder in micronized salbutamol sulfate using moisture sorption analysis. Drug Dev Ind Pharm 33:235-243.
32. Columbano A, Buckton G, Wikeley P. 2002. A study of the crystallization of amorphous salbutamol sulphate using water vapour sorption and near infrared spectroscopy. Int J Pharm 237:171-178.
33. Young PM, Price R. 2004. The influence of humidity on the aerosolisation of micronized and SEDS produced salbutamol sulphate. Eur J Pharm Sci 22: 235-240.
34. Zhu K, Tan RBH, Ng WK, Shen S, Zhou Q, Heng PWS. 2008. Analysis of the influence of relative humidity on the moisture sorption of particles and the aerosolization process in a dry powder inhaler. J Aerosol Sci 39:510-524.
35. Organisation Internationale de Métrologie Légale (OIML). 1996. The scale of relative humidity of air certified against saturated salt solutions. OIML R121.
36. Balani PN, Ng WK, Chan SY, Tan RBH. 2007. Stabilizing crystalline salbutamol sulphate by co-milling. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting; November 11-15; San Diego.
37. Balani PN, Ng WK, Chan SY, Tan RBH. 2007. Effects of co-milling on crystallinity of salbutamol sulphate using adipic acid. American Institute of Chemical Engineers (AIChE) Annual Meeting; November 4-9; Salt Lake City.
38. Willart JF, Dudognon E, Descamps N, Larsson T, Descamps M. 2006. Lactose-based molecular alloys obtained by solid state vitrification. J Non-Cryst Solids 352:4475-4479. (Pubitemid 44646964)
39. Young PM, Price R. 2004. The influence of humidity on the aerosolisation of micronized and SEDS produced salbutamol sulphate. Eur J Pharm Sci 22: 235-240.
40. Telang C, Mujumdar S, Mathew M. 2009. Improved physical stability of amorphous state through acid base interactions. J Pharm Sci 98:2149-2159.
41. Jayasankar A, Somwangthanaroj A, Shao Z, Rodr-guez-Hornedo N. 2006. Co-crystal formation during co-grinding and storage is mediated by amorphous phase. Pharm Res 23:2381-2392.
42. Hyvönen S, Peltonen L, Karjalainen M, Hirvonen J. 2005. Effect of nanoprecipitation on the physicochemical properties of low molecular weight poly(L-lactic acid) nanoparticles loaded with salbutamol sulphate and beclomethasone diproprionate. Int J Pharm 295:269-281.
43. Geeta N, Baggi TR. 1989. An improved spectrophotometric method for the determination of salbutamol sulfate with 3-methylbenzthiazolinone-2-hydrazone. Microchem J 39:137-144.
44. Drapier-Beche N, Fanni J, Parmentier M. 1999. Physical and chemical properties of molecular compounds of lactose. J Dairy Sci 82:2558-2563.
45. Kirk JH, Dann SE, Blatchford CG. 2007. Lactose: A definitive guide to polymorph determination. Int J Pharm 334:103-114.
46. Gusseme AD, Neves C, Willart JF, Rameau A, Descamps M. 2008. Ordering and disordering of molecular solids upon mechanical milling: The case of fananserine. J Pharm Sci 97:5000-5012.
47. Willart JF, Lefebvre J, Danede F, Comini S, Looten P, Descamps M. 2005. Polymorphic transformation of the Γ-form of D-sorbitol upon milling: Structural and nanostructural analyses. Solid State Commun 135:519-524.
48. Otsuka M, Kaneniwa N. 1986. Effect of seed crystals on solid-state transformation of polymorphs of chloramphenicol palmitate during grinding. J Pharm Sci 75:506-511.
49. Dujardin N, Willart JF, Dudognon E, Hédoux A, Guinet Y, Paccou L, Chazallon B. 2008. Solid state vitrification of crystalline α and β-D-glucose by mechanical milling. Solid State Commun 148:78-82.
50. Willart JF, Caron V, Lefort R, Danede F, Prevost D, Descamps M. 2004. A thermal character of solid state amorphization of lactose induced by ball milling. Solid State Commun 132:693-696.
51. Crowley KJ, Zografi G. 2002. Cryogenic grinding of indomethacin polymorphs and solvates: Assessment of amorphous phase formation and amorphous phase physical stability. J Pharm Sci 91: 492-507.
52. Xi SQ, Zhou JG, Wang XT. 2007. Research on temperature rise of powder during high energy ball milling. Powder Metallurgy 50:367-373.
53. 2 during high energy milling. J Mater Sci 35:6015-6026.
54. Descamps M, Willart JF, Dudognon E, Caron V. 2007. Transformation of pharmaceutical compounds upon milling and comilling. J Pharm Sci 96:1398-1407.
55. 5 particles to nanorods. Cryst Growth Des 8:3661-3665.
56. Ng WK, Kwek JW, Tan RBH. 2008. Anomalous particle shift during post-milling storage. Pharm Res 25:1175-1185.
57. Corrigan DO, Corrigan OI, Healy AM. 2006. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers. Int J Pharm 322: 22-30.
58. Martin G, Bellon P. 1997. Driven alloys. Solid State Phys (New York) 50:189-331.